ACTRIMS 2023 | Impact of natalizumab on chronic active MS lesions

Laura Airas, MD, PhD, Turku University Hospital, University of Turku, Turku, Finland, describes a study evaluating the impact of natalizumab treatment on innate immune cell activation at chronic lesion edge using an 18-kDa translocator protein-targeting positron emission tomography (TSPO-PET)-imaging. A total of 10 patients with multiple sclerosis (MS) underwent PET-imaging and conventional MR-imaging before and after 1-year treatment with natalizumab. For comparison, 10 MS patients with no disease-modifying therapy were scanned similarly. The findings showed that the proportions of lesion types were unaltered during a one-year follow-up in both groups. Still, the ratio of active voxels at the chronic active lesion rim was reduced more in the natalizumab-treated group compared to the untreated cohort. This interview took place at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2023 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.